Tag «PHASE 2»

Lorlatinib, лорлатиниб , لورلاتينيب , 洛拉替尼 , PF-6463922

Lorlatinib, PF-6463922 For Cancer; Non-small-cell lung cancer Molecular Formula C21H19FN6O2 Average mass 406.413 Da Phase 2 WO 2013132376 Andrew James Jensen, Suman Luthra, Paul Francis RICHARDSON Applicant Pfizer Inc. (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-4,8- methenopyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile (16R)-19-Amino-13-fluoro-4,8,16-trimethyl-9-oxo-17-oxa-4,5,8,20-tetraazatetracyclo[16.3.1.02,6.010,15]docosa-1(22),2,5,10,12,14,18,20-octaene-3-carbonitrile (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile CAS 1454846-35-5 [RN] UNII:OSP71S83EU лорлатиниб [Russian] لورلاتينيب [Arabic] 洛拉替尼 [Chinese] Ros1 tyrosine kinase receptor inhibitor; Anaplastic lymphoma kinase receptor inhibitor useful for treating cancer mediated by …

MK 0633, SETILEUTON

MK 0633, SETILEUTON (-)-enantiomer 910656-27-8 CAS free form MW 463.3817, C22 H17 F4 N3 O4 FREE FORM Tosylate cas 1137737-87-1 2H-1-Benzopyran-2-one, 4-(4-fluorophenyl)-7-[[[5-[(1S)-1-hydroxy-1-(trifluoromethyl)propyl]-1,3,4-oxadiazol-2-yl]amino]methyl]- 4-(4-Fluorophenyl)-7-[[[5-[(1S)-1-hydroxy-1-(trifluoromethyl)propyl]-1,3,4-oxadiazol-2-yl]amino]methyl]-2H-1-benzopyran-2-one WO2006099735A1 Inventors Thiadiazole substituted coumarin derivatives and their use as leukotriene biosynthesis inhibitor WO 2006099735 A1Marc Blouin, Erich L. Grimm, Yves Gareau, Marc Gagnon, Helene Juteau, Sebastien Laliberte, Bruce Mackay, Richard Friesen, Applicant Merck …

Brigatinib, Бригатиниб, بريغاتينيب , 布格替尼 ,

Brigatinib, AP26113 Molecular Formula: C29H39ClN7O2P Molecular Weight: 584.102 g/mol CAS 1197953-54-0 2,4-Pyrimidinediamine, 5-chloro-N4-[2-(dimethylphosphinyl)phenyl]-N2-[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]- Бригатиниб[Russian][INN] بريغاتينيب[Arabic][INN] 布格替尼[Chinese][INN] 5-chloro-N4-[2-(dimethylphosphinyl)phenyl]-N2-[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-2,4-pyrimidinediamine AP-26113 MFCD29472221 UNII:HYW8DB273J In 2016, orphan drug designation was assigned to the compound in the U.S. for the treatment of ALK, ROS1 or EGFR-positive non-small cell lung cancer (NSCLC). WO 2009143389 PDT PAT Inventors Yihan Wang, Wei-Sheng Huang, Shuangying Liu, …

PIMODIVIR, VX 787

PIMODIVIR VX-787, JNJ-63623872, JNJ-872, VRT-0928787, VX-787, VX 787, VX787, JNJ-872, JNJ 872, JNJ872, VRT-0928787, VRT 0928787, VRT0928787, pimodivir (2S,3S)-3-{[5-fluoro-2-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]amino}bicyclo[2.2.2]octane-2-carboxylic acid (2S,3S)-3-((2-(5-fluoro-1H-pyrrolo[2,3-b]pyridm-3-yl)-5- fluoropyrimidin-4-yl)amino)bicyclo[2.2.2]octane-2-carboxylic acid (2S,3S)-3-((5-Fluoro-2-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl)amino)bicyclo[2.2.2]octane-2-carboxylic Acid MF C20H19F2N5O2, MW 399.4018 CAS 1629869-44-8 PHASE 2 Originator Vertex Pharmaceuticals Developer Janssen Pharmaceuticals Mechanism Of Action Viral polymerase inhibitor, Viral protein inhibitor Who Atc Codes J05A-X (Other antivirals) Ephmra Codes …

Filgotinib

Filgotinib EU 2020/9/24 APPROVED JYSELECA JAPAN APPROVED 2020/9/25 C21H23N5O3S MW425.504 Elemental Analysis: C, 59.28; H, 5.45; N, 16.46; O, 11.28; S, 7.54 1206161-97-8 Cyclopropanecarboxamide, N-[5-[4-[(1,1-dioxido-4-thiomorpholinyl)methyl]phenyl][1,2,4]triazolo[1,5-a]pyridin-2-yl]- G146034 GLPG0634 N-(5-(4-((1,1-dioxidothiomorpholino)methyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide Galapagos Nv INNOVATOR PHASE 3, Crohn’s disease, Rheumatoid arthritis, Ulcerative colitis Filgotinib is an orally available inhibitor of JAK1/JAK2 and TYK2 in phase III clinical development at Galapagos and Gilead for the …

BMS-741672

BMS-741672 N-((1R,2S,5R)-5-(Isopropyl(methyl)amino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino)pyrrolidin-1-yl)cyclohexyl)acetamide BMS-741672 N-((lR,2S,5R)-5-(isopropyl(methyl)amino)-2-((S)-2-oxo-3-(6- (trifluoromethyl)quinazolin-4-ylamino)pyrrolidin-l-yl)cyclohexyl)acetamide N-((1R,2S,5R)-5-(isopropyl(methyl)amino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino)pyrrolidin-1-yl)cyclohexyl)acetamide; C25 H33 F3 N6 O2, 506.56 Acetamide, N-[(1R,2S,5R)-5-[methyl(1-methylethyl)amino]-2-[(3S)-2-oxo-3-[[6-(trifluoromethyl)-4-quinazolinyl]amino]-1-pyrrolidinyl]cyclohexyl]- CAS 1004757-96-3 PHASE 2, , Treatment of Type 2 Diabetes, Agents for Neuropathic Pain Chemokine CCR2 (MCP-1 Receptor) Antagonists Molecular Formula: C25H33F3N6O2 Molecular Weight: 506.574 g/mol Michael G. Yang, Robert J. Cherney Original Assignee Bristol-Myers Squibb Company Michael G. Yang, Robert J. Cherney, Martin G. …

BMS 986001, Censavudine, Festinavir

BMS 986001 Censavudine, Festinavir Has anti-HIV activity. IN PHASE 2 CAS: 634907-30-5, UNII: 6IE83O6NGA, OBP 601, 4′-Ethynyl D4T, 4′-Ed4T, TDK-4-114 Molecular Formula, C12-H12-N2-O4, Molecular Weight, 248.2368 2′,3′-Didehydro-3′-deoxy-4′-ethynylthymidine, 1-((2R,5R)-5-Ethynyl-5-(hydroxymethyl)-2H-furan-2-yl)-5-methyl-pyrimidine-2,4-dione, 2′,3′-Didehydro-3′-deoxy-4′-ethynylthymidine INNOVATOR= YALE UNIVERSITY Festinavir is a nucleoside reverse transcriptase inhibitor (NRTI) which is being developed for the treatment of HIV infection. The drug has shown considerable efficacy in early development, and with perhaps …

Glecaprevir (ABT-493)

Glecaprevir (ABT-493), A-1282576.0 (3aR,7S,10S,12R,21E,24aR)-7-tert-butyl-N-((1R,2R)-2-(difluoromethyl)-1-((1-methylcyclopropane-1-sulfonyl)carbamoyl)cyclopropyl)-20,20-difluoro-5,8-dioxo-2,3,3a,5,6,7,8,11,12,20,23,24a-dodecahydro-1H,10H-9,12-methanocyclopenta(18,19)(1,10,17,3,6)trioxadiazacyclononadecino(11,12-b)quinoxaline-10-carboxamide Cyclopropanecarboxamide, N-((((1R,2R)-2-((4,4-difluoro-4-(3-hydroxy-2-quinoxalinyl)-2-buten-1-yl)oxy)cyclopentyl)oxy)carbonyl)-3-methyl-L-valyl-(4R)-4-hydroxy-L-prolyl-1-amino-2-(difluoromethyl)-N-((1-methylcyclopropyl)sulfonyl)-, cyclic (1->2)-ether, (1R,2R)- CAS RN: 1365970-03-1 UNII: K6BUU8J72P Molecular Formula, C38-H46-F4-N6-O9-S Molecular Weight, 838.8724 Classification Code, Treatment of Chronic Hepatitis C Infection (1R,14E,18R,22R,26S,29S)-N-[(1R,2R)-2-(Difluormethyl)-1-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}cyclopropyl]-13,13-difluor-26-(2-methyl-2-propanyl)-24,27-dioxo-2,17,23-trioxa-4,11,25,28-tetraazapent ;acyclo[26.2.1.03,12.05,10.018,22]hentriaconta-3,5(10),6,8,11,14-hexaen-29-carboxamid (1R,14E,18R,22R,26S,29S)-N-[(1R,2R)-2-(Difluoromethyl)-1-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}cyclopropyl]-13,13-difluoro-26-(2-methyl-2-propanyl)-24,27-dioxo-2,17,23-trioxa-4,11,25,28-tetraazape ;ntacyclo[26.2.1.03,12.05,10.018,22]hentriaconta-3,5(10),6,8,11,14-hexaene-29-carboxamide Class Antivirals (small molecules) Mechanism Of Action Hepatitis C virus NS3 protein inhibitors Who Atc Codes J05A-E (Protease inhibitors) Ephmra Codes J5B1 (Viral hepatitis products) Indication Hepatitis C, Renal …

PF-04136309

PF 4136309 PF4136309; PF 4136309; PF-4136309; PF04136309; PF4136309; PF-04136309; INCB8761; INCB 8761; INCB-8761 (S)-N-(2-(3-((4-hydroxy-4-(5-(pyrimidin-2-yl)pyridin-2-yl)cyclohexyl)amino)pyrrolidin-1-yl)-2-oxoethyl)-3-(trifluoromethyl)benzamide N-[2-[(3S)-3-[[trans-4-Hydroxy-4-[5-(2-pyrimidinyl)-2-pyridinyl]cyclohexyl]amino]-1-pyrrolidinyl]-2-oxoethyl]-3-(trifluoromethyl)benzamide N-[2-((3S)-3-[4-hydroxy-4-(4-pyrimidin-2-ylphenyl)cyclohexyl]aminopyrrolidin-1-yl)-2- oxoethyl]-3-(trifluoromethyl)benzamide 1341224-83-6 MF: C29H31F3N6O3 MW: 568.24097 CC chemokine receptor 2 (CCR2) antagonist Pfizer Limited Gary Burgess PF-4136309, also known as INCB8761, is an orally available human chemokine receptor 2 (CCR2) antagonist with potential immunomodulating and antineoplastic activities. Upon oral …

ACT-334441, Cenerimod an S1P receptor 1 agonist

ACT-334441 Cenerimod UNII-Y333RS1786; Y333RS1786 S1P receptor 1 agonist CAS 1262414-04-9 Chemical Formula: C25H31N3O5 Exact Mass: 453.22637 Actelion Pharmaceuticals Ltd. Martin Bolli, Cyrille Lescop, Boris Mathys,Keith Morrison, Claus Mueller, Oliver Nayler,Beat Steiner, (S)-3-(4-(5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl)-2-ethyl-6-methylphenoxy)propane-1,2-diol (2S)-3-[4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenoxy]propane-1,2-diol (S)-3-{4-[5-(2-Cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol Mechanism Of Action Sphingosine 1 phosphate receptor modulator Who Atc Codes L03A-X (Other immunostimulants) Ephmra Codes L3A (Immunostimulating Agents Excluding Interferons) …